Stock Price
17.10
Daily Change
-3.66%
Monthly
3.83%
Yearly
-54.12%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 18.79 -0.99 -5.01% -66.45%
Acorda Therapeutics 2.86 -0.23 -7.44% 313.59%
Alnylam Pharmaceuticals 188.53 -0.27 -0.14% 45.18%
Alexion Pharmaceuticals 182.50 0 0% 70.54%
Amgen 201.09 -2.88 -1.41% -10.55%
Amarin 3.64 -0.21 -5.45% -20.87%
Arena Pharmaceuticals 57.42 -1.54 -2.61% -12.87%
Arrowhead Research 72.02 -2.02 -2.73% 14.34%
AstraZeneca 8,411.00 -97.00 -1.14% 8.25%
Biogen 242.90 -7.23 -2.89% -0.36%
Bluebird Bio 10.50 -0.26 -2.42% -76.17%
Bristol-Myers Squibb 56.53 -0.28 -0.49% -10.34%
Enanta Pharmaceuticals 91.89 5.00 5.75% 114.20%
Esperion Therapeutics 7.78 0.09 1.17% -71.21%
Galectin Therapeutics 2.57 -0.14 -5.17% -3.02%
Gilead Sciences 70.27 0.20 0.29% 17.06%
GlaxoSmithKline 1,510.80 -29.20 -1.90% 9.19%
Intercept Pharmaceuticals 17.10 -0.65 -3.66% -54.12%
Incyte Corp 68.38 1.64 2.46% -17.86%
Ionis Pharmaceuticals 29.05 -0.71 -2.39% -42.18%
Eli Lilly 260.37 -1.63 -0.62% 76.59%
Moderna Inc 329.63 56.24 20.57% 159.49%
Neurocrine Biosciences 86.98 -0.88 -1.00% -8.98%
Novartis 74.72 -1.85 -2.42% -7.82%
PTC Therapeutics 38.06 -1.35 -3.43% -40.52%
Regeneron Pharmaceuticals 643.35 -4.83 -0.75% 25.15%
Sangamo BioSciences 8.45 -0.49 -5.48% -16.50%
Sarepta Therapeutics 79.62 -1.36 -1.68% -42.78%
Vertex Pharmaceuticals 183.59 -2.65 -1.42% -19.02%

Indexes Price Day Year
NASDAQ 15492 -353.57 -2.23% 26.92%

Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. The Company’s product candidates include Ocaliva (obeticholic or OCA) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to commercializing OCA for PBC, it is also developing OCA for additional indications, including NASH. The Company is also developing product candidates in various stages of clinical and preclinical development.